Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Eiger Biopharma (NQ: EIGR )

11.02 USD -0.84 (-7.08%)
Official Closing Price Updated: 6:03 PM EST, Jan 15, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All news about Eiger Biopharma

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Eiger BioPharmaceuticals Appoints Regulatory Expert and Industry Veteran Christine Murray, MS, RAC to its Board of Directors
Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of therapies for rare and ultra-rare diseases, announced today the appointment of Christine Murray, MS,... 
From PR Newswire
Report: Exploring Fundamental Drivers Behind Cronos Group, Henry Schein, Argo Group International, Eiger BioPharmaceuticals, China Automotive, and Moleculin Biotech — New Horizons, Emerging Trends, an
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Cronos Group Inc.... 
From GlobeNewswire News Releases
Eiger Announces Breakthrough Therapy Designation Granted by FDA for Lonafarnib in Progeria and Progeroid Laminopathies
- Survival Benefit in Children with Progeria Published in JAMA 2018 
From PR Newswire
Eiger Announces PRIME Designation Granted by European Medicines Agency for Lonafarnib for Treatment of Hepatitis Delta Virus Infection
- Phase 3 HDV "D-LIVR" International Study Initiating 
From PR Newswire
Eiger Announces Breakthrough Therapy Designation Granted by FDA for Lonafarnib for Treatment of Hepatitis Delta Virus (HDV) Infection
- Phase 3 HDV "D-LIVR" International Study Initiating 
From PR Newswire
Eiger BioPharmaceuticals Reports on 2018 R&D Day
-- Late Stage Rare and Ultra-Rare Disease Pipeline Advancing 
From PR Newswire
Top Buys by Directors: Mayer III's $248.8K Bet on EIGR
The directors of a company tend to have a unique inside view into the business, so when directors make major buys, investors are wise to take notice. Presumably the only reason a director of a company... 
Tags Stocks
From Market News Video
Eiger BioPharmaceuticals to Host R&D Day in New York City
Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced it will host an R&D Day on... 
From PR Newswire
The Daily Biotech Pulse: ASH Presentations Take The Spotlight, Eiger Gets A New CFO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting ... 
Tags RHHBY Benzinga AMPH
From Benzinga
Eiger BioPharmaceuticals Announces the Appointment of Sri Ryali as Chief Financial Officer
Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced the appointment of Sri Ryali as... 
From PR Newswire
Eiger BioPharmaceuticals (EIGR) Shares Cross Above 200 DMA
In trading on Monday, shares of Eiger BioPharmaceuticals Inc (EIGR) crossed above their 200 day moving average of $11.12, changing hands as high as $11.22 per share. Eiger BioPharmaceuticals Inc shares... 
Tags Stocks
From Market News Video
Eiger BioPharmaceuticals Announces FDA Acceptance of IND Application for Lonafarnib for the Treatment of Progeria and Progeroid Laminopathies
- Plans to File NDA in 2019 
From PR Newswire
36 Biggest Movers From Friday
Gainers Orchids Paper Products Company (NYSE: TIS) shares climbed 164.71 percent to close at $1.80 after the company announced a ... 
Tags STG News Market News
From Benzinga
Analysis: Positioning to Benefit within Artisan Partners Asset Management, Gamco Investors, Eiger BioPharmaceuticals, Waddell & Reed Financial, AmpliPhi Biosciences, and Limbach — Research Highlights
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Artisan Partners Asset... 
From GlobeNewswire News Releases
Eiger to Participate in Piper Jaffray Healthcare Conference
Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced that David Cory, President and CEO, will present... 
From PR Newswire
Eiger Bio Reports Third Quarter 2018 Financial Results
- HDV Phase 3 D-LIVR study start in 2018 and Progeria NDA planned in 2019 
From PR Newswire
Eiger BioPharmaceuticals Prices Previously Announced Public Offering of Common Stock
Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), a clinical-stage biopharmaceutical company focused on the accelerated development and commercialization of targeted therapies for rare and ultra-rare... 
From PR Newswire
The Daily Biotech Pulse: Regulus Soars On Positive Pre-Clinical Data, Biogen Earnings, Proteostasis And Eiger to Offer Shares
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks None of the stocks hit ... 
Tags SCYX FLXN BLCM
From Benzinga
Eiger BioPharmaceuticals Announces Proposed Public Offering of Common Stock
Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced that it has commenced an underwritten public... 
From PR Newswire
Eiger BioPharmaceuticals Receives FDA Rare Pediatric Disease (RPD) Designation for Lonafarnib for the Treatment of Progeria and Progeroid Laminopathies and Plans NDA Filing in 2019
- Designation Enables Priority Review Voucher Eligibility Upon NDA Approval 
From PR Newswire
Eiger BioPharmaceuticals to Participate at BTIG Biotech Conference
Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced the Eiger management team will participate and... 
From PR Newswire
The Daily Biotech Pulse: Novartis Buys Endocyte, Proteostasis Positive Cystic Fibrosis Trial, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting ... 
Tags MBRX Biotech NVS
From Benzinga
46 Biggest Movers From Yesterday
Gainers Yulong Eco-Materials Limited (NASDAQ: YECO) shares climbed 571.05 percent to close at $10.20 on Wednesday after the ... 
Tags CZR BLNK JP
From Benzinga
Eiger BioPharmaceuticals Announces Positive Phase 2 LIMT Study End of Treatment Data with Pegylated Interferon Lambda Monotherapy in Hepatitis Delta Virus (HDV) Infection
- Lambda Antiviral Activity Demonstrated in HDV Infection 
From PR Newswire
36 Stocks Moving In Wednesday's Mid-Day Session
Gainers Yulong Eco-Materials Limited (NASDAQ: YECO) shares jumped 134 percent to $3.557 after the company earlier announced it is ... 
Tags Top Gainers IBP Losers
From Benzinga
Morning Call For Wednesday, Oct. 17
Dec E-mini S&Ps (ESZ18 -0.31%) this morning are down -0.25% ahead of the FOMC meeting. European stocks are down -0.09%, led by losses in automakers. 
Tags Stocks / Equities Bonds Commodities
From Blogs - TalkMarkets
The Daily Biotech Pulse: Eiger's Lymphoedema Drug Study Fails, Roche's Sales Rise
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting ... 
Tags IPCI ENDP EVLO
From Benzinga
Eiger BioPharmaceuticals Announces Positive Results in Phase 2 PREVENT Study of Avexitide Targeting GLP-1 in Post-Bariatric Hypoglycemia (PBH)
- Primary and Secondary Endpoints Achieved with Statistical Significance 
From PR Newswire
Eiger BioPharmaceuticals Announces Phase 2 ULTRA Results of Ubenimex in Lower Leg Lymphedema: Study Did Not Meet Primary or Secondary Endpoint
Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced Phase 2 ULTRA study results in primary and... 
From PR Newswire
Eiger BioPharmaceuticals to Participate in Investor Conferences
Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced that David Cory, President and... 
From PR Newswire
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.